Intravenous versus subcutaneous immunoglobulin therapy in multifocal motor neuropathy

Not Applicable

Completed

• Conditions: Intravenous or subcutaneous immunoglobulin therapy, multifocal motor neuropathy; Nervous System Diseases; Motor neuron disease

• Registration Number: ISRCTN66618743
• Lead Sponsor: Academic Medical Centre (AMC) (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-06-27
• Study Completion: 2009-06-01
• Last Update Posted: 18 October 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

1. All adult patients (greater than 18 years) with signs and symptoms consistent with MMN that fulfill the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria for definite MMN and are being treated with IVIg for at least six months at regular intervals of at most six weeks
2. Patients have to have stable disease for at least six months before inclusion

Exclusion Criteria

1. Use of drugs which are known to cause motor neuropathy
2. Patient and/or partner is/are unable to administer SCIg at home
3. Other diseases known to cause neuropathy or to reduce mobility
4. Diseases known to lead to severe handicap or death at short notice
5. A known selective Immunoglobulin A (IgA) deficiency with anti-IgA antibodies
6. Refusal to give informed consent or withdrawal of previously given permission
7. Legally incompetent adult

Study & Design

• Study Type: Interventional
• Study Design: Not specified